- Home
- AMPY vs EDIT Comparison
AMPY vs EDIT Comparison
Compare AMPY & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMPY | EDIT |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.6M | 202.1M |
| IPO Year | 2011 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AMPY | EDIT |
|---|---|---|
| Price | $4.75 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 607.1K | ★ 2.0M |
| Earning Date | 03-04-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $275,827,100.00 | $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.27 | $0.91 |
| 52 Week High | $6.55 | $4.54 |
Technical Indicators
Market Signals| Indicator | AMPY | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 44.69 |
| Support Level | $4.59 | $2.05 |
| Resistance Level | $4.95 | $2.17 |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 54.93 | 28.25 |
Price Performance
Historical ComparisonAbout AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.